Cargando…
Corrigendum to “Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy” [Heliyon 4 (12) (December 2018) e01039]
Autores principales: | Wu, Xiaosheng, Li, Yanli, Liu, Xin, Chen, Chunhua, Harrington, Susan M., Cao, Siyu, Xie, Tiancheng, Pham, Tu, Mansfield, Aaron S., Yan, Yiyi, Kwon, Eugene D., Wang, Liewei, Ling, Kun, Dong, Haidong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426698/ https://www.ncbi.nlm.nih.gov/pubmed/30937406 http://dx.doi.org/10.1016/j.heliyon.2019.e01309 |
Ejemplares similares
-
Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy
por: Wu, Xiaosheng, et al.
Publicado: (2018) -
ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance
por: Orme, Jacob J., et al.
Publicado: (2020) -
A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors
por: Barham, Whitney, et al.
Publicado: (2023) -
CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1
por: Yin, Peng, et al.
Publicado: (2016) -
B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells
por: Liu, Xin, et al.
Publicado: (2016)